Loading filing...
| Seq | Description | Type | Size | |
|---|---|---|---|---|
| 1 | 10-Q | 10-Q | 1611.0 KB | Open in viewerDownload |
| Concept | Value | Unit |
|---|---|---|
Total Assetsus-gaap:Assets | 13,780,000,000 | USD |
Total Assetsus-gaap:AssetsCurrent | 2,776,000,000 | USD |
Total Cash And Cash Equivalents At Carrying Valueus-gaap:CashAndCashEquivalentsAtCarryingValue | 268,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product)us-gaap:CostOfGoodsAndServicesSold | 482,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product And Service Other)us-gaap:CostOfGoodsAndServicesSold | 1,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product, us-gaap: Operating Segments, blco: Surgical)us-gaap:CostOfGoodsAndServicesSold | 133,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product And Service Other, us-gaap: Operating Segments, blco: Vision Care)us-gaap:CostOfGoodsAndServicesSold |
| 2 | EX-10.2 | EX-10.2 | 102.5 KB | Open in viewerDownload |
| 3 | EX-10.3 | EX-10.3 | 103.9 KB | Open in viewerDownload |
| 4 | EX-10.4 | EX-10.4 | 34.5 KB | Open in viewerDownload |
| 5 | EX-31.1 | EX-31.1 | 9.3 KB | Open in viewerDownload |
| 6 | EX-31.2 | EX-31.2 | 9.3 KB | Open in viewerDownload |
| 7 | EX-32.1 | EX-32.1 | 6.0 KB | Open in viewerDownload |
| 8 | EX-32.2 | EX-32.2 | 6.0 KB | Open in viewerDownload |
| 9 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | EX-101.SCH | 62.1 KB | Download |
| 10 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | EX-101.CAL | 91.3 KB | Download |
| 11 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | EX-101.DEF | 349.1 KB | Download |
| 12 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | EX-101.LAB | 749.6 KB | Download |
| 13 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | EX-101.PRE | 565.2 KB | Download |
| 15 | IDEA: XBRL DOCUMENT | HTML | 51.7 KB | Open in viewerDownload |
| 16 | IDEA: XBRL DOCUMENT | HTML | 130.3 KB | Open in viewerDownload |
| 17 | IDEA: XBRL DOCUMENT | HTML | 9.7 KB | Open in viewerDownload |
| 18 | IDEA: XBRL DOCUMENT | HTML | 110.1 KB | Open in viewerDownload |
| 19 | IDEA: XBRL DOCUMENT | HTML | 36.7 KB | Open in viewerDownload |
| 20 | IDEA: XBRL DOCUMENT | HTML | 59.3 KB | Open in viewerDownload |
| 21 | IDEA: XBRL DOCUMENT | HTML | 97.8 KB | Open in viewerDownload |
| 22 | IDEA: XBRL DOCUMENT | HTML | 9.3 KB | Open in viewerDownload |
| 23 | IDEA: XBRL DOCUMENT | HTML | 12.3 KB | Open in viewerDownload |
| 24 | IDEA: XBRL DOCUMENT | HTML | 60.7 KB | Open in viewerDownload |
| 25 | IDEA: XBRL DOCUMENT | HTML | 15.0 KB | Open in viewerDownload |
| 26 | IDEA: XBRL DOCUMENT | HTML | 13.5 KB | Open in viewerDownload |
| 27 | IDEA: XBRL DOCUMENT | HTML | 85.8 KB | Open in viewerDownload |
| 28 | IDEA: XBRL DOCUMENT | HTML | 11.0 KB | Open in viewerDownload |
| 29 | IDEA: XBRL DOCUMENT | HTML | 70.0 KB | Open in viewerDownload |
| 30 | IDEA: XBRL DOCUMENT | HTML | 14.1 KB | Open in viewerDownload |
| 31 | IDEA: XBRL DOCUMENT | HTML | 65.8 KB | Open in viewerDownload |
| 32 | IDEA: XBRL DOCUMENT | HTML | 40.8 KB | Open in viewerDownload |
| 33 | IDEA: XBRL DOCUMENT | HTML | 11.8 KB | Open in viewerDownload |
| 34 | IDEA: XBRL DOCUMENT | HTML | 18.6 KB | Open in viewerDownload |
| 35 | IDEA: XBRL DOCUMENT | HTML | 12.5 KB | Open in viewerDownload |
| 36 | IDEA: XBRL DOCUMENT | HTML | 18.3 KB | Open in viewerDownload |
| 37 | IDEA: XBRL DOCUMENT | HTML | 43.9 KB | Open in viewerDownload |
| 38 | IDEA: XBRL DOCUMENT | HTML | 125.9 KB | Open in viewerDownload |
| 39 | IDEA: XBRL DOCUMENT | HTML | 8.2 KB | Open in viewerDownload |
| 40 | IDEA: XBRL DOCUMENT | HTML | 30.8 KB | Open in viewerDownload |
| 41 | IDEA: XBRL DOCUMENT | HTML | 50.0 KB | Open in viewerDownload |
| 42 | IDEA: XBRL DOCUMENT | HTML | 9.5 KB | Open in viewerDownload |
| 43 | IDEA: XBRL DOCUMENT | HTML | 84.9 KB | Open in viewerDownload |
| 44 | IDEA: XBRL DOCUMENT | HTML | 11.9 KB | Open in viewerDownload |
| 45 | IDEA: XBRL DOCUMENT | HTML | 107.8 KB | Open in viewerDownload |
| 46 | IDEA: XBRL DOCUMENT | HTML | 12.8 KB | Open in viewerDownload |
| 47 | IDEA: XBRL DOCUMENT | HTML | 43.5 KB | Open in viewerDownload |
| 48 | IDEA: XBRL DOCUMENT | HTML | 37.1 KB | Open in viewerDownload |
| 49 | IDEA: XBRL DOCUMENT | HTML | 10.6 KB | Open in viewerDownload |
| 50 | IDEA: XBRL DOCUMENT | HTML | 17.1 KB | Open in viewerDownload |
| 51 | IDEA: XBRL DOCUMENT | HTML | 15.1 KB | Open in viewerDownload |
| 52 | IDEA: XBRL DOCUMENT | HTML | 116.0 KB | Open in viewerDownload |
| 53 | IDEA: XBRL DOCUMENT | HTML | 16.9 KB | Open in viewerDownload |
| 54 | IDEA: XBRL DOCUMENT | HTML | 24.7 KB | Open in viewerDownload |
| 55 | IDEA: XBRL DOCUMENT | HTML | 9.1 KB | Open in viewerDownload |
| 56 | IDEA: XBRL DOCUMENT | HTML | 10.3 KB | Open in viewerDownload |
| 57 | IDEA: XBRL DOCUMENT | HTML | 37.3 KB | Open in viewerDownload |
| 58 | IDEA: XBRL DOCUMENT | HTML | 39.9 KB | Open in viewerDownload |
| 59 | IDEA: XBRL DOCUMENT | HTML | 32.9 KB | Open in viewerDownload |
| 60 | IDEA: XBRL DOCUMENT | HTML | 42.9 KB | Open in viewerDownload |
| 61 | IDEA: XBRL DOCUMENT | HTML | 36.3 KB | Open in viewerDownload |
| 62 | IDEA: XBRL DOCUMENT | HTML | 22.7 KB | Open in viewerDownload |
| 63 | IDEA: XBRL DOCUMENT | HTML | 19.7 KB | Open in viewerDownload |
| 64 | IDEA: XBRL DOCUMENT | HTML | 17.6 KB | Open in viewerDownload |
| 65 | IDEA: XBRL DOCUMENT | HTML | 14.8 KB | Open in viewerDownload |
| 66 | IDEA: XBRL DOCUMENT | HTML | 19.2 KB | Open in viewerDownload |
| 67 | IDEA: XBRL DOCUMENT | HTML | 9.7 KB | Open in viewerDownload |
| 68 | IDEA: XBRL DOCUMENT | HTML | 33.4 KB | Open in viewerDownload |
| 69 | IDEA: XBRL DOCUMENT | HTML | 13.6 KB | Open in viewerDownload |
| 70 | IDEA: XBRL DOCUMENT | HTML | 22.0 KB | Open in viewerDownload |
| 71 | IDEA: XBRL DOCUMENT | HTML | 22.0 KB | Open in viewerDownload |
| 72 | IDEA: XBRL DOCUMENT | HTML | 15.3 KB | Open in viewerDownload |
| 73 | IDEA: XBRL DOCUMENT | HTML | 42.3 KB | Open in viewerDownload |
| 74 | IDEA: XBRL DOCUMENT | HTML | 159.5 KB | Open in viewerDownload |
| 75 | IDEA: XBRL DOCUMENT | HTML | 34.4 KB | Open in viewerDownload |
| 76 | IDEA: XBRL DOCUMENT | HTML | 33.9 KB | Open in viewerDownload |
| 77 | IDEA: XBRL DOCUMENT | HTML | 13.8 KB | Open in viewerDownload |
| 78 | IDEA: XBRL DOCUMENT | HTML | 25.3 KB | Open in viewerDownload |
| 79 | IDEA: XBRL DOCUMENT | HTML | 30.1 KB | Open in viewerDownload |
| 80 | IDEA: XBRL DOCUMENT | HTML | 17.9 KB | Open in viewerDownload |
| 81 | IDEA: XBRL DOCUMENT | HTML | 4.3 KB | Open in viewerDownload |
| 82 | IDEA: XBRL DOCUMENT | HTML | 16.5 KB | Open in viewerDownload |
| 83 | IDEA: XBRL DOCUMENT | HTML | 41.5 KB | Open in viewerDownload |
| 84 | IDEA: XBRL DOCUMENT | HTML | 13.0 KB | Open in viewerDownload |
| 85 | IDEA: XBRL DOCUMENT | HTML | 4.4 KB | Open in viewerDownload |
| 86 | IDEA: XBRL DOCUMENT | HTML | 8.5 KB | Open in viewerDownload |
| 87 | IDEA: XBRL DOCUMENT | HTML | 42.3 KB | Open in viewerDownload |
| 88 | IDEA: XBRL DOCUMENT | HTML | 9.3 KB | Open in viewerDownload |
| 89 | IDEA: XBRL DOCUMENT | HTML | 25.7 KB | Open in viewerDownload |
| 90 | IDEA: XBRL DOCUMENT | HTML | 14.7 KB | Open in viewerDownload |
| 91 | IDEA: XBRL DOCUMENT | HTML | 73.7 KB | Open in viewerDownload |
| 92 | IDEA: XBRL DOCUMENT | HTML | 41.7 KB | Open in viewerDownload |
| 93 | IDEA: XBRL DOCUMENT | CSS | 2.6 KB | Download |
| 94 | IDEA: XBRL DOCUMENT | JS | 0.9 KB | Download |
| 96 | IDEA: XBRL DOCUMENT | XML | 44.7 KB | Download |
| 99 | IDEA: XBRL DOCUMENT | JSON | 1089.2 KB | Download |
| 100 | IDEA: XBRL DOCUMENT | ZIP | 324.5 KB | Download |
| 101 | IDEA: XBRL DOCUMENT | XML | 1447.2 KB | Download |
| 999 | Full raw SEC SGML submission | Full Submission Text | 9536.7 KB | Open in viewerDownload |
| 0 |
| USD |
Cost Of Goods And Services Sold (us-gaap: Product, us-gaap: Operating Segments, blco: Vision Care)us-gaap:CostOfGoodsAndServicesSold | 271,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product, us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:CostOfGoodsAndServicesSold | 78,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product And Service Other, us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:CostOfGoodsAndServicesSold | 1,000,000 | USD |
Cost Of Goods And Services Sold (us-gaap: Product And Service Other, us-gaap: Operating Segments, blco: Surgical)us-gaap:CostOfGoodsAndServicesSold | 0 | USD |
Total Costs And Expensesus-gaap:CostsAndExpenses | 1,211,000,000 | USD |
Total Earnings Per Share Basicus-gaap:EarningsPerShareBasic | -0.2 | USDPERSHARE |
Total Earnings Per Share Dilutedus-gaap:EarningsPerShareDiluted | -0.2 | USDPERSHARE |
Total Income Tax Expense Benefitus-gaap:IncomeTaxExpenseBenefit | 6,000,000 | USD |
Total Interest Expense Debtus-gaap:InterestExpenseDebt | 97,000,000 | USD |
Total Liabilitiesus-gaap:Liabilities | 7,328,000,000 | USD |
Total Liabilitiesus-gaap:LiabilitiesCurrent | 1,820,000,000 | USD |
Long Term Debt (blco: Senior Secured Notes Due January2031, us-gaap: Secured Debt)us-gaap:LongTermDebt | 769,000,000 | USD |
Long Term Debt (us-gaap: Revolving Credit Facility, blco: Revolving Credit Facility Due June2030, us-gaap: Line Of Credit)us-gaap:LongTermDebt | 100,000,000 | USD |
Total Long Term Debtus-gaap:LongTermDebt | 5,039,000,000 | USD |
Long Term Debt (blco: Other)us-gaap:LongTermDebt | 14,000,000 | USD |
Long Term Debt (blco: Term Loan Due September2028, us-gaap: Secured Debt)us-gaap:LongTermDebt | 0 | USD |
Long Term Debt (blco: Refinancing Term Facility January2031, us-gaap: Secured Debt)us-gaap:LongTermDebt | 2,768,000,000 | USD |
Long Term Debt (blco: Senior Secured Notes Due October2028, us-gaap: Secured Debt)us-gaap:LongTermDebt | 1,388,000,000 | USD |
Long Term Debt (blco: Term Loan Due January2031, us-gaap: Secured Debt)us-gaap:LongTermDebt | 0 | USD |
Long Term Debt (blco: Revolving Credit Facility Due June2030, us-gaap: Secured Debt)us-gaap:LongTermDebt | 100,000,000 | USD |
Total Net Cash Provided By Used In Operating Activitiesus-gaap:NetCashProvidedByUsedInOperatingActivities | 32,000,000 | USD |
Total Net Incomeus-gaap:NetIncomeLoss | -71,000,000 | USD |
Operating Income Loss (us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:OperatingIncomeLoss | 66,000,000 | USD |
Operating Income Loss (us-gaap: Operating Segments, blco: Vision Care)us-gaap:OperatingIncomeLoss | 202,000,000 | USD |
Total Operating Income Lossus-gaap:OperatingIncomeLoss | 33,000,000 | USD |
Operating Income Loss (us-gaap: Operating Segments)us-gaap:OperatingIncomeLoss | 277,000,000 | USD |
Operating Income Loss (us-gaap: Corporate Non Segment)us-gaap:OperatingIncomeLoss | -161,000,000 | USD |
Operating Income Loss (us-gaap: Operating Segments, blco: Surgical)us-gaap:OperatingIncomeLoss | 9,000,000 | USD |
Total Payments To Acquire Property Plant And Equipmentus-gaap:PaymentsToAcquirePropertyPlantAndEquipment | 100,000,000 | USD |
Total Research And Development Expense Excluding Acquired In Process Costus-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | 101,000,000 | USD |
Research And Development Expense Excluding Acquired In Process Cost (us-gaap: Operating Segments, blco: Vision Care)us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | 10,000,000 | USD |
Research And Development Expense Excluding Acquired In Process Cost (us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | 22,000,000 | USD |
Research And Development Expense Excluding Acquired In Process Cost (us-gaap: Operating Segments, blco: Surgical)us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | 13,000,000 | USD |
Total Retained Earnings Accumulated Deficitus-gaap:RetainedEarningsAccumulatedDeficit | -1,002,000,000 | USD |
Total Revenue From Contract With Customer Excluding Assessed Taxus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,244,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,239,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product And Service Other)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 5,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Overthe Counter Products)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 444,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Brandedand Other Generic Products, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 0 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Device Products, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 253,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Pharmaceutical Products, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 0 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Device Products, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 0 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Operating Segments, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 711,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 305,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Brandedand Other Generic Products)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 49,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Operating Segments)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,244,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Pharmaceutical Products)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 266,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 711,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Other Revenues)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 5,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 305,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 228,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Device Products)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 480,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Operating Segments, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 228,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Pharmaceutical Products, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 265,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product, us-gaap: Operating Segments)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,239,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Overthe Counter Products, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 0 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Overthe Counter Products, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 444,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Brandedand Other Generic Products, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 10,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Overthe Counter Products, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 0 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Brandedand Other Generic Products, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 39,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Other Revenues, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 3,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Other Revenues, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Device Products, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 227,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product And Service Other, us-gaap: Operating Segments)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 5,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Pharmaceutical Products, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (blco: Other Revenues, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product And Service Other, us-gaap: Operating Segments, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 3,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product, us-gaap: Operating Segments, blco: Vision Care)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 708,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product, us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 304,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product, us-gaap: Operating Segments, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 227,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product And Service Other, us-gaap: Operating Segments, blco: Surgical)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,000,000 | USD |
Revenue From Contract With Customer Excluding Assessed Tax (us-gaap: Product And Service Other, us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | 1,000,000 | USD |
Total Selling General And Administrative Expenseus-gaap:SellingGeneralAndAdministrativeExpense | 544,000,000 | USD |
Selling General And Administrative Expense (srt: Affiliated Entity)us-gaap:SellingGeneralAndAdministrativeExpense | 2,000,000 | USD |
Selling General And Administrative Expense (us-gaap: Operating Segments, blco: Vision Care)us-gaap:SellingGeneralAndAdministrativeExpense | 228,000,000 | USD |
Selling General And Administrative Expense (us-gaap: Operating Segments, blco: Pharmaceuticals)us-gaap:SellingGeneralAndAdministrativeExpense | 138,000,000 | USD |
Selling General And Administrative Expense (us-gaap: Operating Segments, blco: Surgical)us-gaap:SellingGeneralAndAdministrativeExpense | 73,000,000 | USD |
Total Stockholders Equityus-gaap:StockholdersEquity | 6,379,000,000 | USD |
Total Weighted Average Number Of Shares Outstanding Basicus-gaap:WeightedAverageNumberOfSharesOutstandingBasic | 355,200,000 | SHARES |
